Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Public ClinicalTrials.gov record NCT00168740. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.
Study identification
- NCT ID
- NCT00168740
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 150 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1995 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Sep 15, 2005
Started 1995
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | — | — |
| City of Hope Natioal Medical Center | Duarte | California | — | — |
| Scripps Memorial Hospital | La Jolla | California | — | — |
| UCSD Stem Cell Laboratory | La Jolla | California | — | — |
| Hoag Hospital | Newport Beach | California | — | — |
| Sutter Cancer Center | Sacramento | California | — | — |
| Sidney Kimmel Cancer Center | San Diego | California | — | — |
| University of California, San Francisco | San Francisco | California | — | — |
| Stanford University Medical Center | Stanford | California | — | — |
| Kaiser Permanente Medical Center | Vallejo | California | — | — |
| Rocky Mountain Cancer Center | Denver | Colorado | — | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | — | — |
| Robert H. Lurie Cancer Center, Northwestern University | Chicago | Illinois | — | — |
| University of Iowa General Hospital | Iowa City | Iowa | — | — |
| University of Kentucky Medical Center | Lexington | Kentucky | — | — |
| Louisiana State University | Shreveport | Louisiana | — | — |
| University of Maryland Cancer Center | Baltimore | Maryland | — | — |
| Michigan State University | East Lansing | Michigan | — | — |
| St. Louis University Medical Center | St Louis | Missouri | — | — |
| Roswell Park Cancer Center | Buffalo | New York | — | — |
| University of Rochester Cancer Center | Rochester | New York | — | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | — | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | — | — |
| The West Clinic, P.C. | Memphis | Tennessee | — | — |
| Texas Oncology, P.A. | Dallas | Texas | — | — |
| M.D. Anderson Cancer Center | Houston | Texas | — | — |
| University of Texas Health Sciences Center | San Antonio | Texas | — | — |
| University of Virginia | Charlottesville | Virginia | — | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00168740, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2005 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00168740 live on ClinicalTrials.gov.